Alex Bentley, an 1851 Industrial Fellow working with GSK and the University of Strathclyde, discusses how his research into protein degraders will benefit drug discovery efforts across the pharmaceutical industry. First proposed in the early 2000s, targeted protein degradation (TPD) has emerged as a therapeutic modality with the potential to transform the treatment of disease associated with […]
To read this content in full, you need to login.
Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!